Microcap Ledger Grace Therapeutics, Inc. $GRCE
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Princeton, NJ
- Fiscal year end
- March 31
- Shares outstanding
- 21,035,930 [10-Q 2026-08-13]
What the company doesAI summary of filing
Grace Therapeutics develops clinical-stage drug candidates that apply novel drug delivery technologies to existing pharmaceutical compounds to treat rare and orphan diseases. The company has three drug candidates in development, with GTx-104, an injectable nimodipine formulation for aneurysmal subarachnoid hemorrhage, as its lead program; GTx-104 completed a Phase 3 trial and an NDA was submitted to the FDA in June 2025, though the company received a Complete Response Letter in April 2026 citing manufacturing and non-clinical deficiencies. GTx-102 and GTx-101 are no longer receiving internal development funding as of June 2026, though the company retains intellectual property rights and is exploring out-licensing opportunities. The company is pre-revenue and relies on a network of third-party contract manufacturing organizations to produce its drug candidates. [10-K 2026-06-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 3 months to Jun 2026 | — | −$15.79M | −$3.22M | $13.76M | [10-Q 2026-08-13] |
| FY ended Mar 2026 | — | −$7.79M | −$8.87M | $16.98M | [DEF 14A 2026-07-28] |
| FY ended Mar 2025 | — | −$9.57M | −$14.90M | $22.13M | [DEF 14A 2026-07-28] |
- Quarterly cash burn
- −$3.22M
- Cash runway Estimate
- ~12.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 10,139,861 | [10-Q 2024-11-13] |
| 2025-02-12 | 13,416,735 | [10-Q/A 2025-02-19] |
| 2025-06-19 | 13,828,562 | [10-K 2025-06-23] |
| 2025-08-11 | 13,828,562 | [10-Q 2025-08-12] |
| 2025-11-13 | 15,474,026 | [10-Q/A 2025-11-17] |
| 2026-02-12 | 15,474,026 | [10-Q 2026-02-12] |
| 2026-06-15 | 16,274,026 | [10-K 2026-06-18] |
| 2026-08-11 | 21,035,930 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-08-24; declared effective 2026-08-31 [S-3 2026-08-24]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-05 | Opaleye Management Inc. | buy | 1,694 | $2.06 | [4 2026-10-05] |
| 2026-10-02 | Opaleye Management Inc. | buy | 20,000 | $2.07 | [4 2026-10-05] |
| 2026-10-01 | Opaleye Management Inc. | buy | 38,796 | $2.04 | [4 2026-10-05] |
| 2026-09-29 | Opaleye Management Inc. | buy | 7,849 | $2.09 | [4 2026-10-01] |
| 2026-09-23 | Opaleye Management Inc. | buy | 5,318 | $2.10 | [4 2026-09-23] |
| 2026-09-21 | Opaleye Management Inc. | buy | 9,771 | $2.10 | [4 2026-09-23] |
| 2026-09-09 | Opaleye Management Inc. | buy | 5,836 | $2.09 | [4 2026-09-10] |
| 2026-09-08 | Opaleye Management Inc. | buy | 9,393 | $2.10 | [4 2026-09-10] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-18 | 8-K | Shareholder vote results |
| 2026-08-24 | S-3 | Registration statement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-07-28 | DEF 14A | Proxy statement |
| 2026-07-28 | 8-K | Other events |
| 2026-06-18 | 8-K | Other events |
| 2026-06-18 | 8-K | Results of operations |
Alerts for $GRCE
Email me when Grace Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.